Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

Summary

This study evaluates the efficacy of the combination of olaparib, durvalumab, and fulvestrant for the treatment of patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer with BRCA gene alterations or alterations of genes involved in homologous recombination repair (HRR) or microsatellite instability (MSI) status.

Timeline

Start

2019-08-26

Primary completion

2023-11-15

Completion

2027-08

Publications

• Guiu S, Balmana J, Lemercier P, Follana P, Goncalves A, Bigot F, Frenel JS, Brain E, Mailliez A, Chakiba Brugere C, Curtit E, Derbel O, Dalenc F, Derquin F, Duhoux F, Canon JL, Pimentel I, Chevalier LM, Buisson A, Guyonneau C, Lemonnier J, Delaloge S, Bachelot T. Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2- Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial. Clin Cancer Res. 2025 Nov 14;31(22):4633-4643. doi: 10.1158/1078-0432.CCR-24-4221.

Drugs

Indications